Author | Kevin Kunzmann

Articles

Plaque Psoriasis Treated With Secukinumab Not Affected by Comorbid Psoriatic Arthritis

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.